Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Blood
|
January 2, 2025
Down with dex!
Susan Harding, Joseph Mikhael
Blood
|
December 24, 2016
Pee no more? Urine light chains down the drain
Joseph Mikhael
Blood
|
August 30, 2011
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma
Robert Griffiths, Joseph Mikhael, Michelle Gleeson, et al.
Blood
|
December 31, 2010
An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia
Mark D Danese, Robert I Griffiths, Michelle Gleeson, et al.
Blood
|
March 14, 2019
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Joseph Mikhael, Paul Richardson, Saad Z Usmani, et al.
Blood
|
June 11, 2014
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Yuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, et al.
Blood
|
October 12, 2017
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar, Jonathan L Kaufman, Cristina Gasparetto, et al.
Blood
|
January 15, 2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Paul G Richardson, David S Siegel, Ravi Vij, et al.
Blood
|
October 23, 2013
Smoldering multiple myeloma requiring treatment: time for a new definition?
Angela Dispenzieri, A Keith Stewart, Asher Chanan-Khan, et al.
Blood
|
October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Shaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Blood
|
January 2, 2025
Down with dex!
Susan Harding, Joseph Mikhael
Blood
|
December 24, 2016
Pee no more? Urine light chains down the drain
Joseph Mikhael
Blood
|
August 30, 2011
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma
Robert Griffiths, Joseph Mikhael, Michelle Gleeson, et al.
Blood
|
December 31, 2010
An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia
Mark D Danese, Robert I Griffiths, Michelle Gleeson, et al.
Blood
|
March 14, 2019
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Joseph Mikhael, Paul Richardson, Saad Z Usmani, et al.
Blood
|
June 11, 2014
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Yuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, et al.
Blood
|
October 12, 2017
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar, Jonathan L Kaufman, Cristina Gasparetto, et al.
Blood
|
January 15, 2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Paul G Richardson, David S Siegel, Ravi Vij, et al.
Blood
|
October 23, 2013
Smoldering multiple myeloma requiring treatment: time for a new definition?
Angela Dispenzieri, A Keith Stewart, Asher Chanan-Khan, et al.
Blood
|
October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Shaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Page
of 1